ARC101 in Advanced Solid Tumors (NCT06672185)

🧪 Interventions in This Study

• ARC101 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (13 Sites)

• Massachusetts General Hospital — Boston, Massachusetts
• START Midwest — Grand Rapids, Michigan
• START San Antonio, LLC. — San Antonio, Texas
• Sunshine Coast University Private Hospital — Birtinya, Queensland
• Cancer Research SA — Adelaide, South Australia
• Cabrini Health Research — Malvern, Victoria
• BC Cancer Research Centre — Vancouver, British Columbia
• The Princess Margaret Cancer Centre — Toronto, Ontario
• Jewish General Hospital — Montreal, Quebec
• McGill University Health Centre — Montreal, Quebec
• Rambam Medical Center — Haifa,
• Sheba Medical Center — Ramat Gan,
• Sourasky Medical Center — Tel Aviv,

📞 Contact the Study Coordinator

Phone: (267) 589-9444

Email: clinicaltrials@thirdarcbio.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Solid Tumor

• Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
• A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
• QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
• A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
• First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
• A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas

Explore by condition: All Advanced Solid Tumor clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.